nm23基因在结肠癌中表达及其临床意义

目的:阐明nm23基因产物在结肠癌中表达意义及其与淋巴结转移、预后的关系。方法:用免疫组化方法研究53例结肠癌中nm23基因产物表达。结果:53例结肠癌病例中nm23基因表达阴性29例占54.7%,阳性24例占36.3%。29例阴性表达病例中,发生淋巴结转移23例占79.3%,5年生存率为31.0%(9/29)。低表达的37例均属于C2、D期。低分化腺癌和黏液腺癌占36例。提示nm23基因的低表达与结肠癌的组织学分型、局部淋巴结转移、临床分期及预后有关系。而与肿瘤的大小、部位无关。结论:检测结肠癌组织中nm23基因产物表达可预测肿瘤的转移、复发及预后。     

nm23-H1基因表达与鼻咽癌的早发转移

目的探讨nm23-H1基因产物的表达与鼻咽癌早发转移的关系.方法应用免疫组化S-P法对95例鼻咽癌组织蜡块进行nm23-H1检测.结果nm23-H1的阳性表达率为47.4%(45/95),早发转移组nm23-H1阳性率(26.7%)低于无转移组(60.0%),差异有统计学意义(P＜0.05).nm23-H1表达与临床分期无关.结论nm23-H1阴性表达与鼻咽癌早发转移有关,nm23-H1的表达水平可能是预测中晚期鼻咽癌远处转移的一个重要的生物学指标.     

nm23—H1的表达与大肠癌淋巴结转移相关性的研究

目的:研究大肠癌组织nm23-H_1的表达及其与淋巴结转移的关系.方法:应用免疫组化S-P法检测52例大肠癌标本中nm23-H_1的表达.结果:52例大肠癌原发瘤标本表达阳性率为96.1%(50/52),其中nm23-H_1高表达占59.6%(31/52).nm23-H_1低表达者19例(36.5%,19/52),包括有淋巴结转移者18例(94.7%,18/19).而有淋巴结转移的28例中,低表达者18例(64.2%,18/28).结论:大肠癌淋巴结转移与nm23-H_1表达水平呈负相关,表明nm23-H_1基因是肿瘤转移抑制基因之一.     

nm23/NDPK在胰腺癌中表达和临床意义

目的　探讨胰腺癌中nm2 3表达水平与胰腺癌淋巴结转移、临床分期、神经浸润及预后的关系。方法　应用免疫组织化学法对 3 0例胰腺癌中nm2 3表达水平进行研究。结果　胰腺癌中nm2 3的表达率为 46.67% ,明显高于正常胰腺组织 ;胰腺癌中nm2 3的表达水平与胰腺癌淋巴转移 ,临床分期密切相关 (P <0 .0 5、P <0 .0 1) ,与神经浸润无关 (P>0 .0 5 ) ;nm2 3阳性表达组预后明显低于阴性表达组 (P <0 .0 0 5 )。结论　nm2 3的表达与胰腺癌恶性度及预后相关。     

Expression of nm23-H1 gene product in nasopharyngeal carcinoma and its clinical significance

Objective: The nm23 gene is one of the tumor metastatic suppressor genes. The expression of nm23-H1 has been reported to be inversely associated with metastatic potentiality in a number of human carcinomas, including breast, colorectal, gastric, hepatocellular and gallbladder carcinomas. In this study, the immunohisto-chemical staining of nm23-H1 protein in human naso-pharyngeal carcinoma (NPC) was examined, and the relationship between nm23-H1 and both metastasis and prognosis of patients with NPC was also investigated. Methods: Routine LSAB immunohistochemistry with the nm23-H1 monoclonal murine antibody was employed to study the expression of nm23-H1 protein in 95 paraffin-embedded specimens of NPC treated at our hospital. The clinical pathologic data and results of follow-up were also retrieved. Comparisons between patients with and without expression of nm23-H1 protein with respect to metastasis, loco-regional recurrence and survival were performed using Log rank test. Multivariate prognostic analyses were performed by using Cox’s regression model. Results: Nm23-H1 negative expressive tumors were associated with a higher incidence of lymph-node metastasis (86.7%) than those of nm23-H1 positive (48.6%,P<0.01). Nm23-Hl negative expressive tumors were associated with a high incidence of recurrence and distant metastasis after radiotherapy (P<0.05). A significant association was found between expression of nm23-H1 and prognosis (P<0.01). The expression of nm23-H1 indicated favorable prognosis. Conclusion: It was suggested that nm23-H1 negative expression was significantly associated with lymph-node metastasis, recurrence and distant metastasis. Nm23-H1 may have value for predicting the prognosis of NPC.     

nm23基因在乳腺癌中的表达及临床意义

目的研究nm23基因在乳腺癌中的表达及临床意义。方法应用免疫组化染色对65例资料完整有7年随访结果的原发性乳腺癌nm23基因蛋白染色进行检测。结果65例患者nm23基因高表达36例,低表达29例,转移和非转移组nm23基因低与高表达有显著性差异(P＜0.005),nm23低表达易发生转移。生存5年以上和5年以下的两组患者nm23表达有显著性差异(P＜0.005)。nm23表达与年龄、病理类型、临床分期相关。结论nm23基因表达和乳腺癌的转移、预后有关。联合考虑nm23基因的表达高低和强度,才能更合理的判定转移,并可筛选出具有潜在高转移危险的患者。     

抑癌基因p16和转移抑制基因nm 23在卵巢上皮性肿瘤中的表达

目的:探讨抑癌基因p16及转移抑制基因nm23与卵巢上皮性肿瘤病理特点及生物学行为的关系。方法:免疫组化SP法检测30例正常卵巢,50例卵巢上皮性良性肿瘤及50例卵巢癌组织中P16蛋白和nm23蛋白,并分析其阳性表达与肿瘤的关系。结果:nm23蛋白在卵巢癌组织中的阳性率(70.0%)明显高于正常卵巢(43.3%)及良性肿瘤组(44.0%)(P<0.05);在浆液性癌(87.5%)和粘液性癌(47.8%)中的阳性差率也有显著差异(P<0.05);特别是在有淋巴结转移(39.1%)和无淋巴结转移(92.6%)的中检出率相非常显著(P<0.01),而与卵巢癌的临床分期及病理分级无明显相关性。p16蛋白在卵巢癌中的检出率(26.0%)明显低于正常卵巢(80.0%)和良性上皮性肿瘤(52.0%)(P<0.01),在晚期肿瘤中的表达率(20.5%)也远低于早期肿瘤(63.6%),而且在高度恶性组织中表达水平(11.1%)与中低度恶性组织的表达水平(43.5%)也有显著差异(P<0.05)。结论:nm23基因的表达与卵巢癌的淋巴结转移等生物学行为有关,p16基因可作为临床判断预后的重要指标之一。nm23、p16基因与卵巢上皮性肿瘤的发生、发展密切相关。     

鼻咽癌组织中EGFR和nm23基因表达与预后关系研究

Objective To evaluate the prognostic value of the expression of epidermal growth factor receptor (EGFR) and nm23 in patients with nasopharyngeal carcinoma (NPC). Methods From 2003 to 2006, 127 NPC patients who had undergone biopsy before radiotherapy were reviewed retrospectively. All patients received intensity-modulated radiotherapy using 6 MV X-rays combined with platinum-based chemotherapy. Immunohistochemistry SP method was adopted to detect the expression of EGFR and nm23 in NPC biopsy specimens . The relationship between the expression of EGFR and nm23 and survival was analyzed. Results The positive rate of EGFR and nm23 were 80.3% and 47. 2% respectively. The nm23expression was correlated with distant metastasis (χ2=7.03, P = 0. 008 ). The 5-year estimated local control, over-all survival (OS) and disease-free survival (DFS) were 58.3% ,53.5% and 46. 5%. Patients with negative expression of EGFR had a significantly better 5-year OS, DFS (χ2=8.23, P=0.004;χ2=5.25,P=0.022) than those with positive expression. Patients with positive expression of nm23 had a significantly higher 5-year OS (χ2=15.68, P = 0. 000) and DFS (χ2=14. 85, P = 0. 000) than those with negative expression. The clinical stage, EGFR and nm23 expression were independent prognostic factors shown by Cox proportional hazard model (χ2=23.03, 18.33, 39.92, P= 0.000, 0.000, 0.000).Conclusions The EFGR and nm23 expression were correlated with the prognosis in NPC patients.     

癌基因 C-erb B2抑癌基因nm23在鼻咽癌中的表达及其意义

目的　为探求原癌基因C erbB2 和抗癌基因nm2 3蛋白产物与鼻咽癌的关系。方法　采用免疫组织化学方法 ,对 5 1例鼻咽癌组织中原癌基因C erbB2 和抗癌基因nm2 3蛋白产物进行了检测 ,随访 4年 ,收集复发 (死亡 )组与未复发 (存活 )组 ,进行回顾性研究 ,对两组间蛋白阳性率的差别进行统计比较。结果　鼻咽癌组c erbB2 蛋白的阳性率为 6 8.6 3% (35 / 5 1) ,nm2 3蛋白的阳性率为 39.2 2 % (2 0 / 5 1) ;未分化癌组c erbB2 蛋白的阳性率 81.81% (9/ 11) ,显著高于高分化癌组 5 8.33% (7/ 12 ) (P<0 .0 5 ) ;高分化癌组的nm2 3蛋白的阳性率 5 0 % (6 / 12 ) ,显著高于未分化癌组 2 7.2 7% (3/ 11) (P <0 .0 5 ) ;复发及死亡组c erbB2 蛋白的阳性率 (77.78% ,2 1/ 2 7;79.17% ,19/ 2 4 ) ,明显高于未复发及存活组 (5 8.33% ,14 / 2 4 ;5 9.2 6 % ,16 / 2 7) (P <0 .0 5 ) ;复发及死亡组nm2 3蛋白的阳性率 (33.33% ,9/ 2 7;2 5 % ,6 / 2 4 ) ,显著低于未复发及存活组 (5 4 .17% ,13/ 2 4 ;5 1.85 % ,14 / 2 7) (P <0 .0 5 ) ;c erbB2 蛋白阳性组、nm2 3蛋白阴性组 ,复发或死亡的发生概率分别显著高于c erbB2 蛋白阴性组、nm2 3蛋白阳性组。结论　原癌基因c erbB2 和抗癌基因nm2 3蛋白的表达、评估预后及复发的分     

nm23－H1和CD44蛋白在鼻咽癌中的表达及其与临床的关系

目的：探讨鼻咽癌（ＮＰＣ）中ｎｍ２３－Ｈ１和ＣＤ４４的表达及其与临床的关系。方法：收集ＮＰＣ蜡块标本,应用免疫组化ＬＳＡＢ法,检测ｎｍ２３－Ｈ１和ＣＤ４４基因蛋白的表达,其中前者４８例,后者４０例,３７例同时进行了上述两种检测,将两种基因蛋白表达结果与其临床的关系进行研究分析。结果：ｎｍ２３－Ｈ１阳性表达率６０．４２％,其与颈淋巴结转移无关,但与转移之颈淋巴结大小有关;ｎｍ２３－Ｈ１的表达与放疗后     

EVALUATION OF THE PROGNOSTIC VALUE OF nm23 GENE EXPRESSION IN BREAST CANCER

Mortality of breast cancer is almost due to subsequent metastases, but the micrometastasis is difficult to be detected. Early diagnosis of distant metastasis is a key to improve prognosis of breast cancer. The nm23 gene is a putative metastasis suppressor gene originally identified in murine melanoma cells. The purpose of this study was to investigate the relationship between nm23 gene expression (mRNA and protein) and distant metastasis of breast cancer. MATERIALS AND METHODS Pati…     

癌转移抑制基因nm23在人肺癌中的转录表达研究

目的　探讨nm23基因在人肺癌发生、发展中的作用。方法　采用狭缝印迹杂交技术和非放射性地高辛标记检测系统,检测了143份不同部位、不同性质人肺组织中的nm23H1和nm23H2基因的mRNA表达。结果　nm23H1和nm23H2基因的mRNA表达均有从正常肺组织、肺良性病变组织、非癌肺组织、癌灶组织到癌转移淋巴结组织逐渐降低的趋势。其中,肺癌组织的nm23H2基因mRNA表达较正常肺组织显著较低(P<0.05),癌转移淋巴结组织的nm23H1和nm23H2基因mRNA表达均较正常肺组织显著降低(P<0.05)。肺癌组织的nm23基因表达与淋巴结有无癌转移无明显关系(P>0.05)。结论　nm23基因表达降低可能与肺癌发生有关,未发现nm23基因有癌转移抑制作用     

Expression of nm23-Hl and nm23-H2 Proteins in Prostate Carcinoma

The nm 23 gene products/nucleoside diphosphate (NDP) kinase expression in prostate carcinomas and benign hyperplasias was evaluated immunohistochemically. Monoclonal antibodies against nm 23-H1 and nm 23-H2 proteins were prepared using the corresponding proteins fused with glutathione S-transferase as immunogens. Of the 80 cases of nonmetastatic prostate carcinoma examined, 74% (59/80) and 60% (48/80) were immunoreactive for nm 23-H1 or nm 23-H2 protein, respectively. Negative staining for nm 23-H1 occurred in 83% of metastatic lesions, while 34% were negative for nm 23-H2. All primary tumors corresponding to the metastases examined showed positive immunostaining for nm 23-H1, indicating an inverse relationship between expression of this protein and metastatic status. nm 23-H2 protein was detected in 83% of primary tumors and its expression appeared to he significantly correlated to the degree of histological differentiation. In contrast, all cases of benign prostatic hyperplasia showed elevated levels of both nm 23-H1 and nm 23-H2 expression. These data suggest that the nm 23/NDP kinase may play a role in suppressing the expression of malignant potential in prostate carcinomas.     

nm23基因在膀胱移行细胞癌中表达的临床意义

目的 :探讨nm2 3基因产物与膀胱移行细胞癌生物学行为之间的关系。方法 :应用免疫组织化学方法检测 4 5例膀胱移行细胞癌组织nm2 3基因表达。结果 :nm2 3蛋白弥散于胞浆及胞膜 ,nm2 3蛋白表达与膀胱癌分级呈正相关 ,但与分期无关 ,有转移性癌组织nm2 3表达明显高于无转移癌组织 (P<0 .0 0 1)。结论 :nm2 3基因表达是一个判断膀胱移行细胞癌恶性程度有价值的指标     

Northern印迹杂交分析nm23基因在人肺癌中的表达研究

目的探讨ｎｍ２３基因表达在人肺癌中的作用。方法通过Ｎｏｒｔｈｅｒｎ印迹杂交,检测４０例人肺癌组织和１９例非癌肺组织的ｎｍ２３Ｈ１和ｎｍ２３Ｈ２ｍＲＮＡ表达,采用地高辛标记和检测系统显示杂交信号,并分析ｍＲＮＡ表达与肺癌临床特征的关系。结果低分化鳞癌的ｎｍ２３Ｈ２ｍＲＮＡ表达较中高分化鳞癌显著降低（Ｐ＜０．０１）,小细胞肺癌的ｎｍ２３Ｈ１和ｎｍ２３Ｈ２ｍＲＮＡ表达较肺鳞癌明显降低。但在有或无淋巴结转移的原发癌灶组织间,以及肺癌的临床分期间,ｎｍ２３基因ｍＲＮＡ表达差异无显著性（Ｐ＞０．０５）。结论ｎｍ２３基因ｍＲＮＡ表达与肺癌的组织分化有关,未发现其在肺癌中的癌转移抑制作用。     

鼻咽癌组织中nm23-H1基因表达与外周血T-AgNORs水平的关系

目的观察nm23-H1基因产物在鼻咽癌(NPC)中的表达状态,探讨其与NPC的转移及与外周血T淋巴细胞核仁形成区嗜银蛋白(AgNORs)水平的关系.方法采用S-P免疫组化方法检测65例NPC初治患者癌组织中nm23-H1基因产物表达,并对治疗前患者外周血T-AgNORs含量进行检测.结果 nm23-H1基因蛋白表达率为61.5%(40/65).有颈淋巴结转移的患者nm23-H1表达率为51.2%(21/41),低于无颈淋巴结转移患者的79.2%(19/24),两者差异有显著性(χ2=4.99,P<0.05).随访中有15例发生远处转移,其nm23-H1表达率为33.3%(5/15),无转移者为70.0%(35/50),两者差异有显著性(χ2=7.56,P<0.01).nm23-H1表达水平与T分期无关.nm23-H1基因蛋白表达阳性患者外周血T-AgNORs含量显著高于阴性者(t=5.566,P<0.001).结论 nm23-H1基因不仅在抑制NPC的转移中有一定的作用,而且可能与机体的免疫调节机能有关.     

nm23-H1基因在喉癌中杂合性丢失和微卫星序列不稳定性分析及表达的研究

目的　探讨nm2 3 H1基因在喉鳞状细胞癌中杂合性丢失 (LOH)及表达情况。方法　选择nm2 3 H1基因内部及附近 5个微卫星多态标记 ,对 72例喉癌标本进行杂合性丢失和微卫星序列不稳定性检测 ,同时以RT PCR方法分析 38例配对喉鳞状细胞癌标本中nm2 3 H1基因表达情况。结果　LOH涉及至少 1个位点的频率高达 76 .39% ,5个位点均有LOH ,以D17S16 6 5处频率最高 ,达 38.10 %。 3个位点出现MI ,最高为 12 .70 %。nm2 3 H1基因杂合性丢失及微卫星不稳定与淋巴结转移、临床分期和肿瘤分化无显著相关性 (P >0 .0 5 ) ,但D17S16 6 5位点高LOH频率与低分化相关 (P <0 .0 5 )。癌、癌旁及转移淋巴结中nm2 3 H1表达不同 ,但差异无统计学意义 ,表达水平与淋巴结转移无关 (P >0 .0 5 )。结论　nm2 3 H1基因可能在喉鳞癌发生中起作用 ,杂合性丢失可能是影响基因功能的主要机制。     

鼻咽癌组织中EGFR和nm23基因表达与预后关系研究

目的 探讨表皮生长因子受体(EGFR)和转移抑制基因(nm23)表达与鼻咽癌(NPC)患者预后的相关性.方法 回顾分析本院2003-2006年放疗前行鼻咽活检且资料完整的127例经病理证实的鼻咽癌患者,所有患者均采用6 MV X线调强放疗联合顺铂+氟尿嘧啶方案化疗.采用免疫组化链霉素抗生物素蛋白-过氧化物酶法(SP)检...     

青年人大肠癌nm23基因表达及其意义

目的　探讨青年人大肠癌预后差的可能机制。方法　应用免疫组化ABC法检测转移抑制基因nm2 3蛋白产物核苷二磷酸激酶 (NDPK)在大肠癌中的表达。分析 >40岁和≤ 40岁的病人间表达的差异及与预后的关系。结果　nm2 3 (NDPK)的阳性表达率 >40岁组明显高于≤ 40岁组 (P <0 0 5 )。nm2 3 (NDPK)的表达与生存率呈正相关 (P <0 0 5 ) ,与转移复发率呈负相关 (P <0 0 5 )。结论　nm2 3 (NDPK)可作为大肠癌预后的判断指标。nm2 3 (NDPK)的低表达预示着肿瘤的高侵袭性和转移性 ,其可能是青年人大肠癌预后差的原因。     

nm23在胚胎组织和肺癌组织中表达的意义

目的 探讨nm23-H1基因的表达与胚胎组织发育分化的关系和在肺癌组织中表达的意义。方法 对SD大鼠和人的胚胎组织,以及人肺癌组织进行nm23蛋白（NM23－H1）免疫组化检测。结果 NM23－H1的积聚与胚胎发育期间各种上皮组织的分化和器官形成相一致,正常胚胎组织要发育至一定阶段,具有一定空间构型（器官结构）时才有较稳定的NM23－H1积聚。在49例肺癌原发病灶中,NM23－H1阳性率34．7％,其中鳞癌的阳性率27．3％,腺癌的阳性率50．0％,5例未分化大细胞癌均阴性。27例肺门淋巴结转移癌灶的NM－23H1阳性率（22．2％）与原发瘤灶中的阳性率（34．7％）比较差异无显著性（P＞0．05）。在肺癌原发病灶中,NM23－H1阳性与阴性二组间淋巴结转移发生率的差异亦无显著性（P＞0．05）。结论 NM23－H1在胚胎组织和肺癌组织中的积聚与胚胎组织和肺癌组织器官样结构的分化有密切关系,NM23－H1可能对维持稳定的上皮组织结构起着重要的调节作用,NM23－H1似乎不能直接抑制肺癌细胞的转移。